Screener
TG Therapeutics TGTX Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's interest expense?
- TG Therapeutics (TGTX) reported interest expense of $16.57M in Q2 2026.
- How has TG Therapeutics's interest expense changed year-over-year?
- TG Therapeutics's interest expense increased by 146.8% year-over-year, from $6.72M to $16.57M.
- What is the long-term trend for TG Therapeutics's interest expense?
- Over 4 years (2021 to 2025), TG Therapeutics's interest expense has grown at a 47.6% compound annual growth rate (CAGR), from $5.64M to $26.73M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about TG Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude